Citigroup
PGNX

Citigroup’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Citigroup’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-79,324
Closed -$301K – 7814
2020
Q1 		$301K Buy
79,324
+15,605
+24% +$67.2K ﹤0.01% 4358
2019
Q4 		$325K Sell
63,719
-188,504
-75% -$997K ﹤0.01% 4790
2019
Q3 		$1.27M Buy
252,223
+114,929
+84% +$573K ﹤0.01% 3365
2019
Q2 		$847K Buy
137,294
+70,412
+105% +$339K ﹤0.01% 3834
2019
Q1 		$311K Sell
66,882
-497,201
-88% -$2.25M ﹤0.01% 4670
2018
Q4 		$2.37M Buy
564,083
+466,669
+479% +$2.38M ﹤0.01% 2515
2018
Q3 		$611K Sell
97,414
-5,168
-5% -$39.7K ﹤0.01% 4038
2018
Q2 		$825K Sell
102,582
-8,215
-7% -$62.7K ﹤0.01% 3566
2018
Q1 		$827K Sell
110,797
-49,272
-31% -$328K ﹤0.01% 3448
2017
Q4 		$953K Buy
160,069
+4,866
+3% +$29.6K ﹤0.01% 3388
2017
Q3 		$1.14M Sell
155,203
-38,483
-20% -$244K ﹤0.01% 3230
2017
Q2 		$1.31M Buy
193,686
+101,518
+110% +$749K ﹤0.01% 3027
2017
Q1 		$870K Sell
92,168
-74,188
-45% -$740K ﹤0.01% 3364
2016
Q4 		$1.44M Buy
166,356
+151,321
+1,006% +$1.12M ﹤0.01% 3311
2016
Q3 		$95K Buy
15,035
+7,377
+96% +$44.6K ﹤0.01% 5239
2016
Q2 		$32K Sell
7,658
-51,230
-87% -$247K ﹤0.01% 5862
2016
Q1 		$257K Buy
58,888
+52,792
+866% +$235K ﹤0.01% 4845
2015
Q4 		$37K Sell
6,096
-76,070
-93% -$499K ﹤0.01% 6153
2015
Q3 		$470K Buy
82,166
+61,442
+296% +$471K ﹤0.01% 3799
2015
Q2 		$155K Buy
20,724
+4,908
+31% +$29.7K ﹤0.01% 4653
2015
Q1 		$95K Sell
15,816
-11,762
-43% -$74K ﹤0.01% 5066
2014
Q4 		$209K Buy
27,578
+25,016
+976% +$150K ﹤0.01% 4656
2014
Q3 		$14K Buy
2,562
+1,187
+86% +$5.92K ﹤0.01% 6111
2014
Q2 		$6K Sell
1,375
-14,372
-91% -$54.9K ﹤0.01% 6405
2014
Q1 		$64K Sell
15,747
-8,098
-34% -$41.4K ﹤0.01% 5337
2013
Q4 		$127K Buy
23,845
+9,992
+72% +$44K ﹤0.01% 5050
2013
Q3 		$70K Buy
13,853
+9,423
+213% +$51.1K ﹤0.01% 5011
2013
Q2 		$20K Buy
+4,430
New +$19.9K ﹤0.01% 5832

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Citigroup's PGNX Position: Q2 2020 in Review

Citigroup sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 79,324 shares — an estimated $301K sold.

Citigroup first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $2.37M in Q4 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Citigroup reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Citigroup sold 79,324 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $301K.
  • Citigroup first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
  • Citigroup's Progenics Pharmaceuticals Inc position peaked at $2.37M in Q4 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Citigroup's 13F filing for Q2 2020, filed 12 Aug 2020.